ERYTECH Pharma S.A.

ERYTECH Pharma S.A.

ERYP

ERYPERYTECH Pharma S.A. US flag

NASDAQ Global Select

0.78

USD

+0.01

- -

47.38MMarket Cap

CIK

0001624422

ISIN

US29604W1080

CUSIP

29604W108

Return %

Stock

S&P500

1Y

-23.53

26.84

3Y

-88.95

77.03

5Y

-92.98

80.55

Use logarithmic scale

No data availableFinancial data will appear here once available

Capital Structure

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Revenue

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Company Description

CEO: Gil Beyen
Full Time Employees: 49
Sector: Healthcare
Industry: Biotechnology
Address: 60 Avenue Rockefeller Lyon France 69008
IPO Date: Jul 5, 2016
CIK: 0001624422
Website: erytech.com
Similar Companies: Day One Biopharmaceuticals, Inc. (DAWN)
CASI Pharmaceuticals, Inc. (CASIF)
Xeris Biopharma Holdings, Inc. (0A8E.L)
Theseus Pharmaceuticals, Inc. (THRX)
Entrada Therapeutics, Inc. (TRDA)
Longeveron Inc. (LGVN)
Business: ERYTECH Pharma S.A. (Ticker: ERYP), now operating as PHAXIAM Therapeutics S.A. following its merger with Pherecydes Pharma and name change in June 2023, is a clinical-stage biopharmaceutical company that develops innovative therapies based on bacteriophages, or phages, to treat resistant bacterial infections, particularly those caused by multi-drug resistant pathogens; its pipeline targets key bacteria including Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa, which account for over two-thirds of resistant hospital-acquired infections, through individualized phage therapies (IPT) and phage therapies medicinal products (PTMP), supported by proprietary phagogram diagnostic testing for phage susceptibility; previously focused on red blood cell-based therapeutics via the ERYCAPS platform for oncology and orphan diseases, including lead candidate eryaspase (GRASPA) for acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), pancreatic cancer, and triple-negative breast cancer, as well as preclinical erymethionase and eryminase targeting cancer cell metabolism. The company manufactures its therapies at GMP-approved facilities in Lyon, France, and previously in Philadelphia and Princeton, USA, with licensing and distribution partnerships for eryaspase including Orphan Europe (Recordati Group) for ALL and AML in Europe and TEVA for ALL in Israel under the GRASPA brand; it serves patients with high unmet needs in antimicrobial resistance (AMR), a global crisis causing over one million deaths annually, and explores phage applications in food safety, cosmetics, and animal health. Founded in 2004 and headquartered at 60 Avenue Rockefeller, 69008 Lyon, France, the company shifted strategically in 2022-2023 by halting further development of eryaspase after FDA feedback and non-conclusive trial data, implementing deep restructuring, and merging with Pherecydes to pivot to phage therapy leadership; recent developments include US FDA IND approval in Q4 2024 for clinical protocols, a strategic collaboration with Technophage announced in early 2025 to expand its GMP phage portfolio to 25 phages by end-2025 targeting at least seven critical pathogens for IPT expansion, Phase 1/2 trial initiations for urinary tract infections and burn infections, and a process launched in March 2025 to find buyers amid a receivership procedure, with voluntary delisting from Nasdaq planned.

Company News